Australian Indigenous cancer patients’ self-report of diagnosis, treatment and comorbidity data: how does it compare to medical chart review.

2016 ◽  
Vol 4 (2) ◽  
pp. 330 ◽  
Author(s):  
Christina Maresch Bernardes ◽  
Abbey Diaz ◽  
Peter Baade ◽  
Gail Garvey ◽  
Patricia Casarolli Valery

Rationale: The quality of patient-centred care relies upon the reliability of the data used to produce performance measures. The agreement between patient self-report and medical chart review among Aboriginal and Torres Strait Islander cancer patients is unknown.Objective: To examine the concordance between patient self-report and medical chart review in determining cancer type, current and previous cancer treatment, comorbidities and patient characteristics associated with agreement.Method: Aboriginal and Torres Strait Islander cancer patients (≥18 years) who had received cancer treatment in the past 30 days (n=208) were recruited. The prevalence, sensitivity, specificity, total agreement and Kappa coefficients (K) were estimated to determine the agreement (yes + yes; no + no) between self-reported data and medical records.Results: 13.5% of the patients could not accurately identify their cancer type. For treatment variables, raw agreement ranged from 70.5% to 92.4%, although, after correcting for chance, there was a lack of consistency for current radiation and past treatment variables (K= -0.01 to 0.48). Sensitivity and specificity were moderate to high for current surgery and chemotherapy. The greatest crude prevalence difference by data source was observed for comorbidities not specified in the questionnaire. Sensitivity and specificity were high for diabetes. Conclusion: investigators and policy makers may rely upon patient self-report for diabetes, current cancer treatment of surgery and chemotherapy. However, should be cautious when considering patient self-report for past treatment and other comorbid conditions. 

2020 ◽  
Vol Volume 13 ◽  
pp. 1757-1762
Author(s):  
Hilary C Tanenbaum ◽  
Anna Lawless ◽  
Lina S Sy ◽  
Vennis Hong ◽  
Bradley Ackerson ◽  
...  

Author(s):  
Nathalie Aubert ◽  
Isabelle Lyon-Pagès ◽  
Isabelle Carrard ◽  
Michel Suter ◽  
Friedrich Stiefel ◽  
...  

2019 ◽  
Vol 19 (1) ◽  
pp. 14-23 ◽  
Author(s):  
Barbara Dariš ◽  
Mojca Tancer Verboten ◽  
Željko Knez ◽  
Polonca Ferk

The plant Cannabis sativa L. has been used as an herbal remedy for centuries and is the most important source of phytocannabinoids. The endocannabinoid system (ECS) consists of receptors, endogenous ligands (endocannabinoids) and metabolizing enzymes, and plays an important role in different physiological and pathological processes. Phytocannabinoids and synthetic cannabinoids can interact with the components of ECS or other cellular pathways and thus affect the development/progression of diseases, including cancer. In cancer patients, cannabinoids have primarily been used as a part of palliative care to alleviate pain, relieve nausea and stimulate appetite. In addition, numerous cell culture and animal studies showed antitumor effects of cannabinoids in various cancer types. Here we reviewed the literature on anticancer effects of plant-derived and synthetic cannabinoids, to better understand their mechanisms of action and role in cancer treatment. We also reviewed the current legislative updates on the use of cannabinoids for medical and therapeutic purposes, primarily in the EU countries. In vitro and in vivo cancer models show that cannabinoids can effectively modulate tumor growth, however, the antitumor effects appear to be largely dependent on cancer type and drug dose/concentration. Understanding how cannabinoids are able to regulate essential cellular processes involved in tumorigenesis, such as progression through the cell cycle, cell proliferation and cell death, as well as the interactions between cannabinoids and the immune system, are crucial for improving existing and developing new therapeutic approaches for cancer patients. The national legislation of the EU Member States defines the legal boundaries of permissible use of cannabinoids for medical and therapeutic purposes, however, these legislative guidelines may not be aligned with the current scientific knowledge.


BMJ Open ◽  
2016 ◽  
Vol 6 (1) ◽  
pp. e009711 ◽  
Author(s):  
Takahisa Kawano ◽  
Kei Nishiyama ◽  
Hiroshi Morita ◽  
Osamu Yamamura ◽  
Atsuchi Hiraide ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document